17200962

Source:http://linkedlifedata.com/resource/pubmed/id/17200962

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0007138, umls-concept:C0013089, umls-concept:C0030705, umls-concept:C0045093, umls-concept:C0079083, umls-concept:C0144576, umls-concept:C0205179, umls-concept:C0282460, umls-concept:C0332283, umls-concept:C0341697
pubmed:issue	3
pubmed:dateCreated	2007-1-25
pubmed:abstractText	Cisplatin-based therapy is standard in patients with advanced urothelial carcinoma but a large proportion are ineligible due to renal impairment. The safety and activity of a dose-dense carboplatin-based regimen in this patient population were explored.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/0374236
pubmed:citationSubset	AIM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Carboplatin, http://linkedlifedata.com/resource/pubmed/chemical/Deoxycytidine, http://linkedlifedata.com/resource/pubmed/chemical/Doxorubicin, http://linkedlifedata.com/resource/pubmed/chemical/Paclitaxel, http://linkedlifedata.com/resource/pubmed/chemical/gemcitabine
pubmed:status	MEDLINE
pubmed:month	Feb
pubmed:issn	0008-543X
pubmed:author	pubmed-author:BajorinDean FDF, pubmed-author:BoyleMary GMG, pubmed-author:GalskyMatthew DMD, pubmed-author:IasonosAlexiaA, pubmed-author:MironovSvetlanaS, pubmed-author:ScattergoodJosephJ
pubmed:copyrightInfo	(c) 2007 American Cancer Society.
pubmed:issnType	Print
pubmed:day	1
pubmed:volume	109
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	549-55
pubmed:meshHeading	pubmed-meshheading:17200962-Adult, pubmed-meshheading:17200962-Aged, pubmed-meshheading:17200962-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:17200962-Carboplatin, pubmed-meshheading:17200962-Cohort Studies, pubmed-meshheading:17200962-Deoxycytidine, pubmed-meshheading:17200962-Disease-Free Survival, pubmed-meshheading:17200962-Dose-Response Relationship, Drug, pubmed-meshheading:17200962-Doxorubicin, pubmed-meshheading:17200962-Female, pubmed-meshheading:17200962-Humans, pubmed-meshheading:17200962-Kidney Diseases, pubmed-meshheading:17200962-Male, pubmed-meshheading:17200962-Maximum Tolerated Dose, pubmed-meshheading:17200962-Middle Aged, pubmed-meshheading:17200962-Paclitaxel, pubmed-meshheading:17200962-Survival Rate, pubmed-meshheading:17200962-Urinary Bladder Neoplasms
pubmed:year	2007
pubmed:articleTitle	Phase II trial of dose-dense doxorubicin plus gemcitabine followed by paclitaxel plus carboplatin in patients with advanced urothelial carcinoma and impaired renal function.
pubmed:affiliation	Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA. matthew.galsky@usoncology.com
pubmed:publicationType	Journal Article, Clinical Trial, Phase II